The Adherence Math
Blood pressure medication has two half-lives, and confusing them causes most of the trouble. One is the drug's — the hours it lingers in your body after a missed dose. The other is persistence — the months before half of all prescriptions quietly end. This page separates the two, works the arithmetic of once-daily dosing, and gives you the honest missed-dose rules. It is education about how adherence behaves, not instruction in dosing: what to do after a missed dose is a pharmacist-and-prescriber conversation, with one rule that never varies.
What the evidence supports
- About half of people starting a blood pressure medication have stopped within a year — the persistence half-life, measured electronically in the Vrijens study.
- Adherence falls as dosing frequency rises: once-daily regimens consistently beat twice- and three-times-daily ones in meta-analyses.
- Morning versus evening timing makes little difference to outcomes — the TIME trial found no material difference — so the schedule you remember wins.
What remains uncertain
- Why one person forgets and another does not is only partly understood; cost, side effects, and routine each contribute differently by person.
- Which adherence intervention — pillboxes, apps, pharmacist check-ins, single-pill forms — works best in whom has mixed evidence.
- How quickly and completely control slips after a missed dose varies with the drug's half-life and the person's baseline; the general rules are safer than the specific predictions.
Evidence last reviewed: August 20, 2026. Conclusions may change as new research is published.
the handoff conversation
The Two Half-Lives
The word "half-life" gets used for two very different numbers, and keeping them apart changes how you read everything that follows. The drug half-life is pharmacology: how long it takes your body to clear half of a dose. For amlodipine that is long — a day and a half or more — which is why a missed dose barely registers. For many ACE inhibitors and ARBs it is shorter — a matter of hours — which is why a skipped evening shows up in the next day's reading. The persistence half-life is behavior: how long before half of the people who started a prescription are no longer taking it. That number is about a year, and it has nothing to do with chemistry.
The Side-Effect Conversation and Two-Drug Reality pages explain the two biggest reasons persistence fails — symptoms never reported, and regimens too complicated to survive real life. This page adds the arithmetic: what a missed dose actually costs, and why the once-daily form is the strongest single design choice in the whole treatment.
The Missed-Dose Math
The drug half-life sets the shape of the problem. The table below is a rough pharmacokinetic map — bands, not precise numbers, because half-lives vary with age, kidneys, and the specific drug in the class.
| Class | Typical half-life band | What one missed dose tends to do | Reading |
|---|---|---|---|
| 🟢 Long-acting CCBs (amlodipine) | Roughly 30–50 hours | Little — the drug lingers; two missed days start to matter | Forgiving |
| 🟡 ACE inhibitors / ARBs | Roughly 6–12 hours | The next day's reading may run higher; control wobbles | Brittle |
| 🟡 Thiazide diuretics | Roughly 6–15 hours | Similar — a skip shows as a higher reading within a day or two | Brittle |
| 🔴 Beta-blockers (if prescribed) | Variable, often short | Fast heart rate or chest discomfort can appear if stopped abruptly | Never stop abruptly |
The universal rule that never varies: if a dose is missed, do not double up on the next one. Resume the normal schedule and tell the prescriber or pharmacist what happened. For the specifics — whether to take a forgotten pill tonight depends on the drug and the hours — a pharmacist is the right person to ask, and the Question List page carries the exact wording for the next visit.
The Dose-Frequency Curve
Here is the arithmetic the once-daily argument is built on. A classic meta-analysis of antihypertensive studies measured adherence against how many times a day the regimen demanded action:
The slope between the first bar and the last is the whole once-daily argument: each additional daily act costs roughly ten percentage points of adherence. That is why guidelines favor once-daily agents that cover the full 24 hours, why combination pills exist — one act, two classes — and why the parent topic Medications & the Handoff treats "morning or evening?" as a real question rather than a formality.
Morning, Evening, or Just Remembered
The timing question got a definitive answer in 2022, when the TIME trial followed more than 21,000 people randomized to take their usual blood pressure medications in the morning or the evening. Cardiovascular outcomes were essentially identical between the groups — evening dosing does not confer a magic nighttime advantage, and morning dosing does not carry a penalty. What did differ was adherence: the morning group was modestly more likely to stay consistent, because a morning dose can be anchored to a standing habit — coffee, breakfast, toothbrush — while an evening dose competes with the day's end.
The practical conclusion is gentle: the schedule that survives your actual life is the right schedule, and it is a conversation with your prescriber, not a fixed doctrine. What the science protects against is the false belief that there is one perfect hour — the perfect hour is the one that gets taken.
Why People Stop — the Honest List
The persistence half-life has causes, and they are mostly not the ones people confess at visits.
- 🤫 The silent-disease problem — high pressure does not hurt, so the pill feels optional on a day that already feels full.
- 😮💨 Unreported side effects — the cough or the swelling is not mentioned at the visit; the pill is dropped instead. The Side-Effect Conversation page is the fix for this one.
- 💰 Cost anxiety — copays and refill friction end prescriptions silently; asking the pharmacy about generics and single-pill forms is a legitimate move, and skipping doses to save money is not.
- 🧩 Complexity — every extra bottle, refill, or daily act taxes the system; the dose-frequency curve above is the penalty for complexity.
- 📉 The good-numbers trap — a string of excellent home readings can look like proof the medication is unnecessary. The readings are proof it is working; the Home Measurement log is the honest witness, and stopping to test the theory is how the number quietly returns.
⚠️ The missed-dose rules that never vary
Never double a dose to catch up. Never stop, halve, or skip doses to "test" whether you still need them — abrupt stops carry real rebound risk with some classes. Resume at the normal schedule, note it in the log, and tell the prescriber. The safe experiment of reducing or stopping is a supervised one, and only the person who prescribed can run it.
Measuring Your Own Adherence Honestly
Adherence is measurable, and the measurement is embarrassing-free if you frame it as data. Three quick checks give you most of the truth.
- 🧾 The refill gap — pharmacies can print your fill history: if the refill dates drift later than the prescription calendar, the gap is your answer. Bring it to the visit; prescribers see this data every day and no one is surprised by it.
- 📅 The 30-day pillbox test — one month in a weekly pillbox, filled once a week at the same time, converts forgetting from a mystery to a count. The count is the conversation.
- 📓 The log cross-check — when readings drift up, check the two weeks of doses first; the Medication & Supplement Reconciliation audit and the home-measurement log together almost always name the cause.
- 🧑⚕️ The pharmacist loop — pharmacy adherence programs, automatic refills, and synchronization services exist precisely for this problem; a five-minute conversation at the counter is a legitimate medical tool, not a chore.
Questions, Answered Briefly
- ❓ I missed a whole week. Now what? — Resume today at the normal dose; never double up. Tell the prescriber at the next visit, and let the log show the drift so the plan can absorb it.
- ❓ Is evening dosing better for my heart? — The TIME trial found no material difference in outcomes between morning and evening dosing. The schedule that reliably gets taken wins; if you want to switch, say so at the visit.
- ❓ My pharmacy says I'm late on refills. Does that matter if my readings are fine? — It matters exactly as much as the readings: late refills mean lapses, and lapses are the reason readings eventually climb. The refill record and the log together are the honest picture.
- ❓ Can I take two of the low-dose pills to make one big dose? — No — that is self-titration, and it doubles the side-effect risk without doubling the benefit. Dose changes are the prescriber's dial.
- ❓ Does a missed dose explain my high reading this morning? — Maybe — which is why the question is worth asking out loud. If the half-life is short, a skipped dose yesterday is a plausible and reassuring explanation; the pattern across two weeks of the log is the real answer.
The Bottom Line
- Two half-lives, one page. The drug's half-life is hours; persistence is about a year. Confusing them is how people think one missed dose is fine forever, or that a year of silence is a medical event.
- Complexity is a dose in itself. Each additional daily act costs roughly ten percentage points of adherence — the arithmetic behind once-daily drugs and single-pill combinations.
- Timing is personal, not mystical. The TIME trial cleared morning versus evening; the schedule that survives your life is the one that works.
- The missed-dose rules never vary: resume at the normal dose, never double up, never stop abruptly, and let the supervised experiment stay supervised.
Related Topics
- Vrijens B, et al. "Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories." BMJ (2008)
- Iskedjian M, et al. "Relationship between Daily Dose Frequency and Adherence to Antihypertensive Pharmacotherapy: Evidence from a Meta-Analysis." Clinical Therapeutics (2002)
- Claxton AJ, et al. "A Systematic Review of the Associations between Dose Regimens and Medication Compliance." Clinical Therapeutics (2001)
- Mackenzie IS, et al. "Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME): a randomised controlled trial." Lancet (2022)
- Naderi SH, et al. "Adherence to Drugs That Prevent Cardiovascular Disease: Meta-Analysis on 376,162 Patients." American Journal of Medicine (2012)